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in parotid glandDimitrios Andreadis a, Athanasios Poulopoulos a,*, Alexandros Nomikos b,
Apostolos Epivatianos a, Calypso Barbatis ba Department of Oral Medicine and Maxillofacial Pathology, Dental School, Aristotle University of Thessaloniki,
Thessaloniki 54124, Greece
b Department of Histopathology, Red Cross Hospital of Athens, Athens 11526, GreeceReceived 3 October 2005; accepted 5 October 2005Summary Parotid gland is an extremely rare location for primary malignant melanoma and
the majority of reported melanoma cases in parotid appear to represent metastasis from the
skin of head and neck areas. We describe a rare case of a malignant melanoma of the oral cavity
which had metastasized in parotid gland and we present the microscopic and immunohisto-
chemical findings in parotid gland metastasis. Metastatic infiltrations were observed in peri-
and intraparotid lymph nodes and the characteristic microscopic appearance together with
the immunoreactivity of neoplastic cells for vimentin, S-100 protein and HMB-45 established
the final diagnosis.c 2005 Elsevier Ltd. All rights reserved.
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dIntroduction
Primary melanoma of the parotid gland is an extremely rare
event and salivary gland melanomas are nearly always best
regarded as metastases1 associated with in and around the
gland, lymph node metastasis from a head and neck cutane-
ous primary melanoma.2 The routine preoperative diagnos-
tic procedure for parotid melanomas that enable accurate
staging, include computerized tomography, magnetic reso-
nance imaging and fine-needle aspiration cytology (FNAC).3741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reserved
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E-mail address: akpoul@yahoo.gr (A. Poulopoulos).For melanoma patients with clinically palpable lymphade-
nopathy in the region of the parotid gland, most investiga-
tors advocate a therapeutic parotidectomy and ipsilateral
modified radical neck digestion,4 whereas adjuvant radio-
therapy and chemotherapy may also be given. Prognosis is
generally poor, and only rarely, patients may survive a long
period of time following surgery.5
Intraoral melanomas are uncommon accounting for 0.5%
of oral malignancies.6 Nearly 80% of the cases affect hard
palate, the upper and lower gingivae and buccal mucosa.7
They exhibit far more aggressive behaviour than cutaneous
melanomas.8 Despite the anatomic site of the oral melano-
mas, prognosis is quite poor with a 15% five-year survival.
138 D. Andreadis et al.rate.9 Metastases spread to regional lymph nodes, lungs,
liver, brain and bones due to satellite formation, angiolym-
phatic invasion and submucosal spread.10
The aim of our study is to present a rare case of malig-
nant melanoma of parotid gland as a metastasis from the
oral cavity.
Case report
A 65-year-old male, with a history of a treated, oral mela-
noma on the anterior maxillary alveolar ridge, without evi-
dence of any local invasion or distant metastasis, based on
CT images, six months before, was presented again with a
two-month, painful swelling, located to the angle of the right
mandible. FNAC’s findings of the parotid swelling were indic-
ative for a malignant melanoma. A total parotidectomy was
performed in Red Cross Hospital, Athens Greece, and forma-
lin-fixed, paraffin-embedded sections were studied histo-
chemically and immunohistochemically with markers S-100
protein (N 1573, Dakocytomation, Glostrup, A/S Denmark),
vimentin (N 1521, Dakocytomation, Glostrup, A/S Denmark)
and HMB 45 using an Envision/HRP automated technique
(Dakocytomation, Glostrup, A/S Denmark). Antigen retrieval
was performed by microwaving in citrate buffer.
Microscopically, the peri and intraparotid lymph nodes
were infiltrated by malignant melanoma, whereas the adja-Figure 1 (a) The metastatic melanoma in lymph node is separ
eosin · 100). (b) Histologic appearance of metastatic melanoma in p
neoplastic cells showing atypical mitotic figures, areas with me
fibroblastic response (hematoxylin/eosin · 300).
Figure 2 (a) Strong nuclear and cytoplasmic reactivity of neopl
reactivity for HMB45 of the neoplastic cells (envision-HRP · 300).cent parotid tissue was clear (Fig. 1a). Metastatic lesion was
consisted by epithelioid neoplastic cells with foamy cyto-
plasm, marked cytologic and nuclear atypia, nuclear
grooves, large eosinophilic nucleoli, and abundant atypical
mitotic figures. Areas with melanin pigmentation, necrosis
with haemmorage and marked fibroblastic response were
also seen (Fig. 1b).
Immunohistochemically, neoplastic cells showed strong
nuclear and cytoplasmic reactivity for S-100 protein
(Fig. 2a) and immunoreactivity for vimentin and mainly for
HMB45 (Fig. 2b) was also a characteristic consistent feature
of the great majority of the neoplastic cells whereas there
was not immunostaining with AE1/AE3 cytokeratins.
Discussion
Although melanocytes can exist in the intralobular duct of
the parotid gland potentially serving as origin for primary
melanoma,11 almost all cases of parotid melanomas appear
to represent metastatic lesions, often from cutaneous head
and neck primaries.2 Noteworthy, cutaneous melanoma is
the second after squamous cell carcinomas of the head
and neck region most common metastatic tumor of the par-
otid gland, accounting for approximately 40% of cases.5,12
The direct invasion of melanoma from adjacent soft tissue
or skin is a possibility but uncommon way to parotid tissueated from the intact, adjacent parotid tissue (Hematoxylin/
arotid lymph node characterized by infiltration with epithelioid
lanin pigmentation, necrosis with haemmorage and marked
astic cells for S-100 protein (envision-HRP · 300). (b) Immuno-
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sults by intralymphatic spread of tumor in the area of lym-
phatic drainage of the parotid lymph nodes—including
forehead, anterior frontal and temporal region, eyelids
and conjuctiva, lacrimal gland, anterior ear, cranial vault
and posterior cheek regions.13 In contrast, facial, oral,
and anterior oropharyngeal carcinomas commonly metasta-
size to the submandibular lymph nodes and gland.1 The
treatment of choice for primary and metastatic melanoma
in parotid is wide excision, but prognosis even with treat-
ment appears to be poor.14 It has been recommended that
patients undergoing regional lymphadenectomy for primary
melanomas of the ear, face, and anterior scalp, be consid-
ered for parotidectomy as well.15
In contrast to cutaneous melanoma, oral malignant mel-
anoma typically presents a more aggressive vertical growth
phase, with invasion of the underlying submucosa.16 It grows
rapidly, may be flat or raised or nodular, asymptomatic ini-
tially but may later become ulcerated, painful and may
bleed.17 It is more inclined to metastasize into regional
and distant sites or recur locally, exhibiting cervical lymph
node metastases in 5–48% of cases at the time of diagnosis.
Mucosal melanomas have a poor prognosis with a mean sur-
vival rate less than cutaneous accounting for only 17,1%8
and radio-chemotherapy are not effective more than surgi-
cal excision alone.18
Malignant melanoma is easily identified microscopically
because of its junctional activity, diffuse arrangement of
round or spindle cells with abundant eosinophilic cytoplasm,
marked cytologic atypia, nuclear grooves, folds and
pseudoinclusions, large eosinophilic nucleoli, and abundant
mitotic figures, some of them atypical. These findings
are accompanied by prominent melanin pigmentation,
necrosis and invasion of the surrounding tissue. Immunohis-
tochemistry such as positive staining for vimentin, S-100
protein, HMB-45, MART-1/Melan A, tyrosinase, NKI/C-3
and microphthalmia transcription factor (MiTF) aid the diag-
nosis. Vimentin is the most consistent but the least useful
diagnostically. Positivity for S-100 is nonspecific but due
to the fact that S-100 is negative in most of the tumors that
enter in the differential diagnosis, S-100 staining is very
important. HMB 45 is a much more specific marker than S-
100 protein. Melan A is positive in approximately 80% of
melanomas. The positivity of MiTF is in the range of over
90%.17
In conclusion, in cases of head and neck malignant mel-
anomas attention may be given in salivary glands either
have or not any symptoms. Preoperative CT/MRI examina-
tion of head and neck region including major salivary glands
and their lymph nodes is necessary. Furthermore, any post-
operative clinically palpable lymphadenopathy in the region
of the parotid or submandibular gland may be associatedwith a metastasis of malignant melanoma and FNA cytology
detection is necessary for the definition of diagnosis.References
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